Eric Venker, President and CEO of Immunovant, has sold 200,000 shares of Roivant Sciences Ltd. The transaction, reported in a recent SEC filing, took place on November 3, 2026, at an average price of $36.31 per share. This sale is part of a Rule 10b5-1 trading plan established by Venker on June 30, 2026. The move reflects routine management of his equity holdings.

Roivant Sciences, a company focused on pharmaceutical preparations, is listed under the CIK number 0001635088. The firm operates in the pharmaceutical industry, which is characterized by high levels of executive stock transactions as leaders manage their investments and comply with regulations.

According to the filing, Venker now owns 999,154 shares of Roivant following this transaction. The sale was executed in multiple transactions, with prices ranging from $35.75 to $36.70. Venker has committed to providing detailed information about the specific prices at which the shares were sold upon request.

This transaction may impact stakeholders, including investors and analysts monitoring Roivant's stock performance and executive activities. The filing does not specify any immediate next steps following this sale.

Details of the Transaction

The SEC filing indicates that Eric Venker's sale of 200,000 shares was executed under a Rule 10b5-1 trading plan, which allows executives to set up a predetermined schedule for selling shares to avoid accusations of insider trading. This plan was established on June 30, 2026, and is designed to provide a systematic approach to managing stock transactions.

In the filing, it is noted that the shares were sold at a weighted average price of $36.31, with individual transaction prices ranging from $35.75 to $36.70. Venker has committed to providing detailed information regarding the specific number of shares sold at each price upon request, ensuring transparency in the transaction.

Company Information

Roivant Sciences Ltd., where Venker serves as President and CEO of its subsidiary Immunovant, is incorporated in the United Kingdom and operates in the pharmaceutical preparations sector, classified under the Standard Industrial Classification code 2834. The company is recognized for its innovative approaches in the life sciences industry.

The filing also confirms that Venker is not a director or a ten percent owner of Roivant, but holds the position of an officer, specifically as President and CEO of Immunovant. This distinction highlights his role within the corporate structure and the responsibilities associated with managing the subsidiary's operations.

The filing does not include any information regarding the potential impact of this sale on Venker's future compensation or on Roivant's strategic plans.